Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Castle Biosciences Inc
(NQ:
CSTL
)
26.00
+0.35 (+1.36%)
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 27, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
89,818
Open
25.38
Bid (Size)
25.30 (1)
Ask (Size)
26.74 (3)
Prev. Close
25.65
Today's Range
25.38 - 26.35
52wk Range
15.58 - 48.40
Shares Outstanding
25,167,365
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
Top News
More News
Castle Biosciences’ Medical Director to Present at the Precision Medicine World Conference 2023
January 23, 2023
From
Castle Biosciences, Inc.
Via
Business Wire
Data Presentations at 2023 Winter Clinical Dermatology Conference - Hawaii® Support Clinical Value of Castle Biosciences’ Skin Cancer Test Portfolio
January 17, 2023
From
Castle Biosciences, Inc.
Via
Business Wire
Performance
YTD
+14.14%
+14.14%
1 Month
+20.09%
+20.09%
3 Month
+10.97%
+10.97%
6 Month
-7.01%
-7.01%
1 Year
-26.88%
-26.88%
More News
Read More
Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2022 Results
January 08, 2023
From
Castle Biosciences, Inc.
Via
Business Wire
Looking Into Castle Biosciences's Return On Capital Employed
November 16, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
January 05, 2023
Via
Benzinga
Castle Biosciences Receives Accreditation from the College of American Pathologists for its Pittsburgh Clinical Laboratory
November 21, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Research Published in Melanoma Management Finds that 99% of Patients with Uveal Melanoma Tested with DecisionDx®-UM Gain Value from the Results
November 17, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Presents New Data Demonstrating the Clinical Utility and Value of DecisionDx®-SCC in Moderately and Poorly Differentiated Cutaneous Squamous Cell Carcinoma Tumors
November 15, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Named a Houston Chronicle Top Workplace for the Second Consecutive Year
November 14, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
This Analyst With 90% Accuracy Rate Raises PT On Chesapeake Energy; Here Are 5 Stock Picks For Last Week From Benzinga's Most Accurate Analysts
November 07, 2022
Via
Benzinga
This Analyst With 82% Accuracy Rate Boosts PT On Booking Holdings; Here Are 5 Stock Picks For Thursday From Benzinga's Most Accurate Analysts
November 04, 2022
Via
Benzinga
Castle Biosciences Announces Third Quarter 2022 Results
November 02, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences to Present at Upcoming Investor Conferences
November 01, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Real-World Clinical Utility Study Published in Cancer Investigation Demonstrates the Impact of DecisionDx®-SCC Test Results in Guiding Risk-Aligned Care for Patients with Cutaneous Squamous Cell Carcinoma
October 31, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Presents New Data from Collaboration with the National Cancer Institute’s (NCI) Surveillance, Epidemiology and End Results (SEER) Program
October 27, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
New Data Demonstrate that the Utilization of TissueCypher® Barrett’s Esophagus Test Results Can Significantly Improve the Management of Low-Grade Dysplasia in Patients with Barrett’s Esophagus over the Standard of Care Alone
October 25, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Presents New Data Demonstrating the Impact of DecisionDx®-SCC Test Results on the Management of Medicare-Eligible Patients with Cutaneous Squamous Cell Carcinoma and One or More Risk Factors
October 24, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
New Data from DECIDE Study Show the Significant Role of DecisionDx®-Melanoma Test Results and Patient Preference in Decisions to Perform the Sentinel Lymph Node Biopsy (SLNB) Surgical Procedure
October 20, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences to Release Third Quarter 2022 Financial Results and Host Conference Call on Wednesday, Nov. 2
October 19, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Results from a Randomized Controlled Trial Show That TissueCypher® Barrett’s Esophagus Test Results Can Significantly Improve the Accuracy of Risk Assessments and Adherence to Guideline-Recommended Patient Management
October 13, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Presents Case Study Showcasing the Diagnostic Performance of DiffDx®-Melanoma at the College of American Pathologists 2022 (CAP22) Annual Meeting
October 11, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences to Present Data Supporting the Clinical Value of Its Suite of Skin Cancer Tests through Multiple Oral Presentations at the 2022 American Society for Dermatologic Surgery (ASDS) Annual Meeting
October 10, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Announces Publication of Study Demonstrating the Integration of DecisionDx®-Melanoma and Clinicopathologic Factors Provides Optimized, Personalized Survival Prognoses for Patients with Cutaneous Melanoma
September 23, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Presents Clinical Use Scenarios for Its Diagnostic Gene Expression Profile Tests at Maui Derm NP+PA Fall 2022 Conference
September 21, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Presents Foundational Guideposts and Three-Year Financial Targets at 2022 Investor Day
September 20, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.